China Pharma Holdings (CPHI) Equity Ratio (2010 - 2026)

China Pharma Holdings has reported Equity Ratio for 17 years, with the latest figure at 0.82 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 67.29% year-over-year to 0.82; the trailing twelve-month figure through Mar 2026 stood at 0.82 (up 67.29% YoY), and the FY2025 full-year result was 0.73, up 40.95% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.82, up from 0.73 in the prior quarter.
• The five-year high for Equity Ratio was 0.82 in Q1 2026, with the low at 0.17 in Q3 2022.
• Historically, Equity Ratio has averaged 0.43 across 5 years, with a median of 0.47 in 2025.
• Annual changes were most pronounced in 2022 — Equity Ratio slumped 53.59% — and 2023, when it surged 127.51%.
• China Pharma Holdings' Equity Ratio stood at 0.24 in 2022, then surged by 87.64% to 0.45 in 2023, then increased by 14.98% to 0.52 in 2024, then jumped by 40.95% to 0.73 in 2025, then gained by 11.8% to 0.82 in 2026.
• The last three Equity Ratio figures came in at 0.82 (Q1 2026), 0.73 (Q4 2025), and 0.53 (Q3 2025), per Business Quant data.